1.Zhao HF#, Zhou XM#, Wang J, Chen FF, Wu CP, Diao PY, Cai LR, Chen L, Xu YW, Liu J, Li ZY, Liu WL, Chen ZP, Huang GD*, Li WP*. Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients. J Transl Med. 2021;30;19(1):372. (IF=5.531)
2.Zhao HF#, Wu CP#, Zhou XM, Diao PY, Xu YW, Liu J, Wang J, Huang XJ, Liu WL, Chen ZP, Huang GD, Li WP*. Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation. Cancer Cell Int. 2021;21(1):24. (IF=5.722)
3.Zhao HF, Wang G, Wu CP, Zhou XM, Wang J, Chen ZP, To ST*, Li WP*. A multi-targeted natural flavonoid myricetin suppresses lamellipodia and focal adhesions formation and impedes glioblastoma cell invasiveness and abnormal motility. CNS Neurol Disord Drug Targets. 2018;17(7):557-567. (IF=2.761)
4.Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To SST*, Li WP*. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Molecular Cancer. 2017; 16(1):100. (IF=7.776)
5.Zhao HF#, Wang J#, Jiang HR, Chen ZP*, To SS*. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. J Exp Clin Cancer Res. 2016; 35(1):78. (IF=5.189)
6.Zhao HF, Wang J, To SST*. The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: alliance or contradiction? (review). Int J Oncol. 2015; 47(2): 429-436. (IF=3.018)
7.Zhao HF, Li M, Li LM, Yang XM, Lan GB, Zhang Y*. MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PloS one. 2013; 8(12):e83571. (IF=3.5328)
8.Wu CP#, Wu P#, Zhao HF#（共同一作）, Liu WL*, Li WP*. Clinical applications of and challenges in single-cell analysis of circulating tumor cells.DNA & Cell Biology. 2018; 37(2):78-89. (IF=2.918)
9.Wang W#*, Zhao HF#（共同一作）, Yao TF, Gong H. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. Invest New Drugs. 2019;37(1):175-183. (IF=3.534)
10.Wu J#, Su HK#, Yu ZH#, Xi SY, Guo CC, Hu ZY, Qu Y, Cai HP, Zhao YY, Zhao HF, Chen FR, Huang YF, To STT, Feng BH, Sai K*, Chen ZP*, Wang J*. Skp2 modulates proliferation, senescence and tumorigenesis of glioma. Cancer Cell Int. 2020; 20:71.(IF=4.175)
11.Xu YW#, Liao CP#, Liu RL#, Liu J, Chen ZP, Zhao HF, Li ZY, Chen L, Wu CP, Tan H, Liu WL*, Li WP*. IRGM promotes glioma M2 macrophage polarization through p62/TRAF6/NF-κB pathway mediated IL-8 production. Cell Biol Int, 2019;43(2):125-135.
12.Xu YW#, Liu RL#, Liao CP#, Liu J, Zhao HF, Li ZY, Liu WL, Chen L, Wu CP, Tan H, Chen ZP, Xie N*, Li WP*. High expression of immunity-related GTPase family M protein in glioma promotes cell proliferation and autophagy protein expression.Pathol Res Pract. 2019; 215(1):90-96.
13.Liu J#, Zhou Q#, Wu CP#, Xu YW, Liu WL, Zhao HF, Li WP*. SPHK2 protein expression, Ki-67 index and infiltration of tumor-associated macrophages (TAMs) in human glioma. Histology And Histopathology, 2018, 33(9): 987-994.
14.Wang J, Su HK, Zhao HF, Chen ZP*, To ST*. Progress in the application of molecular biomarkers in gliomas. BBRC. 2015; 465(1):1-4. (IF=2.371)
15.Wang J, Zhao YY, Li JF, Guo CC, Chen FR, Su HK, Zhao HF, Long YK, Shao JY, To SST*, Chen ZP*. IDH1 mutation detection by droplet digital PCR in glioma. Oncotarget. 2015; 6(37):39651-60. (IF=5.0079)
16.Wang G*, Wang JJ, Wu W, Tony To SS, Zhao HF, Wang J. Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert Opin Drug Deliv. 2015; 5:1-25. (IF=5.434)
17.Wang G*, Wang JJ, Zhao HF, Wang J, Tony To SS. The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy. Arch Biochem Biophys. 2015;580:84-92. (IF=2.8069)
18.Wang G*, Wang JJ, To SST, Zhao HF, Wang J. Role of SIRT1-mediated mitochondrial and Akt pathways in glioblastoma cell death induced by Cotinus coggygria flavonoid nanoliposomes. Int J Nanomedicine, 2015; 10: 5005-5023. (IF=4.32)
